Preventing Heroin Relapse with Clonidine

Printer-friendly PDF

Study # 407

What is the purpose of the study?
To determine whether clonidine, given to abstinent patients maintained on buprenorphine, prevents relapse to opiate use more effectively than placebo.

Who can participate in the study?
This study is accepting men and women who:

  • Are at least 18 years of age
  • Are physically dependent on heroin
  • Are seeking treatment for opiate addiction
  • Are able to come to the clinic 7 days a week

What will participants be asked to do?
The study lasts up to 36 weeks (9 months).

Participants will:

  • Receive daily buprenorphine as a tablet dissolved under the tongue
  • Provide urine samples 3 times a week
  • Use PDAs (electronic diaries)
  • Be asked to take capsules that may contain clonidine (a drug used to treat high blood pressure) or placebo (a pill with no drug)

Once participants have been on buprenorphine for 6 weeks, they will be asked to abstain from illicit opiates for at least 2 weeks to stay in the study.

Where is the study taking place?
The NIDA Intramural Research Program is located on the Johns Hopkins Bayview Medical Center campus in East Baltimore.

Will there be any cost to participate?
No, there is no charge for study-related medical care, including study visits and procedures.

Will I receive payment of some kind?
You might be able to earn vouchers. The vouchers would be redeemable for store-bought items.

How can I find out if I’m eligible to participate?
Call 1-866- START NOW (1-866-782-7866) for a confidential screening.

This study accepts participants in the following categories: heroin


Home Privacy Contact Us Accessibility FOIA (NIH) About NIDA NIDA NIH HHS USA.gov Teen smokers Smokers Drug Users Comparison Groups